IMNM
(NASDAQ)Immunome, Inc.
$26.12-- (--)
Loading... - Market loading
Immunome (IMNM) Stock Price & Financial Analysis
Immunome Stock Price Chart
Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
Day's Range$26.10 - $26.99
52-Week High$30.06
52-Week Low$8.93
Open$26.43
Volume784.07K
Average Volume (3M)1.07M
Market Cap2.96B
Shares Outstanding113.14M
Price to Sales (P/S)736.02
Price to Book (P/B)5.02
EV/EBITDA-10.45
Revenue (TTM)4.01M
Net Income (TTM)-224.59M
Free Cash Flow (TTM)-205.52M
EPS (TTM)$-2.39
Profit Margin-5593.85%
Operating Margin-5947.90%
Return on Equity (ROE)-38.15%
Debt to Equity0.01
50-Day MA$25.13
200-Day MA$22.41
52-Week Change183.60%
Annual Dividend$0.00
Dividend Yield0.00%
Day's Range$26.10 - $26.99
52-Week High$30.06
52-Week Low$8.93
Open$26.43
Volume784.07K
Average Volume (3M)1.07M
Market Cap2.96B
Shares Outstanding113.14M
Price to Sales (P/S)736.02
Price to Book (P/B)5.02
EV/EBITDA-10.45
Revenue (TTM)4.01M
Net Income (TTM)-224.59M
Free Cash Flow (TTM)-205.52M
EPS (TTM)$-2.39
Profit Margin-5593.85%
Operating Margin-5947.90%
Return on Equity (ROE)-38.15%
Debt to Equity0.01
50-Day MA$25.13
200-Day MA$22.41
52-Week Change183.60%
Annual Dividend$0.00
Dividend Yield0.00%
Frequently Asked Questions About Immunome
What is the current stock price for IMNM?
As of the latest trading session, IMNM stock trades at $26.12. The 52-week range is $8.93–$30.06, with a day range of $26.10–$26.99.
What is the P/E ratio for IMNM?
The P/E ratio (Price-to-Earnings) for IMNM is shown in the Key Statistics section. This valuation metric helps compare Immunome, Inc. to industry peers.
Does IMNM pay dividends?
Immunome does not currently pay a regular dividend. The company reinvests earnings into growth and operations. Check the Dividends tab for historical dividend information.
What do analysts recommend for IMNM?
Based on 6 analysts, the consensus for IMNM is Buy.
What is the market cap of IMNM?
Immunome's market capitalization is $2.96B, classifying it as a mid-cap company. Immunome operates in the Healthcare sector within the Biotechnology industry.